Ahmet TEKTEMUR, Ebru ÖNALAN, Süleyman Serdar KOCA, Ahmet YILDIRIM, Servet YOLBAŞ, Sibel OYUCU ORHAN, Nevzat GÖZEL, İbrahim Hanifi ÖZERCAN

Octreotide ameliorates dermal fibrosis in bleomycin-induced scleroderma

Background/aim: Insulin-like growth factor (IGF)-I is a differentiation and growth factor. Antifibrotic action of octreotide has beenreported in pulmonary fibrosis. The present study aimed to research the prophylactic and therapeutic potential of octreotide on ableomycin (BLM)-induced experimental scleroderma model.Materials and methods: Sixty Balb/c female mice were divided into 6 groups. Daily subcutaneous BLM (100 µg) was injected for 3weeks in groups II and III and for 6 weeks in groups V and VI. Octreotide (100 µg/kg per day) was injected subcutaneously for the first3 weeks in group III (prophylactic) and the second 3 weeks in group VI (therapeutic). Mice in groups I, II, and III were sacrificed at theend of the third week, while mice in groups IV, V, and VI were sacrificed at the end of the sixth week.Results: Repeated BLM applications increased dermal inflammatory cell counts and dermal thickness, and led to dermal fibrosis at boththe third and sixth weeks. Moreover, mRNA expressions of TGF-β1 and IGF binding protein (IGFBP)-3 and -5 were higher in the BLMinjected sham groups. On the other hand, IGFBP-3 and -5 mRNA expressions were significantly decreased in both the prophylactic andtherapeutic octreotide groups. Similarly, octreotide decreased dermal inflammatory infiltrations and dermal thickness.Conclusion: Octreotide has antifibrotic actions on experimentally induced dermal fibrosis. It can be suggested that IGF-I playspathogenic roles, and octreotide is a candidate for research in the treatment of scleroderma.

PDF

___

Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-567.
Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2: 134-144.
Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 2007; 9: S4.
Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004; 16: 733-738.
Koca SS, Ozgen M, Dagli F, Tuzcu M, Ozercan IH, Sahin K, Isik A. Proteasome inhibition prevents development of experimental dermal fibrosis. Inflammation 2012; 35: 810-817.
Veraldi KL, Feghali-Bostwick CA. Insulin-like growth factor binding proteins-3 and -5: central mediators of fibrosis and promising new therapeutic targets. Open Rheumatol J 2012; 6: 140-145.
Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
Rothe MJ, Altman RD, Falanga V. Plasma somatomedin-C levels in systemic sclerosis. Br J Dermatol 1988; 119: 639-642.
Harrison NK, Cambrey AD, Myers AR, Southcott AM, Black CM, du Bois RM, Laurent GJ, McAnulty RJ. Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci (Lond) 1994; 86: 141-148.
Fawzi MM, Tawfik SO, Eissa AM, El-Komy MH, Abdel-Halim MR, Shaker OG. Expression of insulin-like growth factor-I in lesional and non-lesional skin of patients with morphoea. Br J Dermatol 2008; 159: 86-90.
Feghali CA, Wright TM. Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum 1999; 42: 1451-1457.
Knauer AV, Medsger TA. Wright TM, Feghali CA. Insulin-like growth factor binding proteins contribute to the increased extracellular matrix production by fibroblasts from patients with systemic sclerosis (SSc). Arthritis Rheum 2001; 44: 378.
Krein PM, Winston BW. Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. Chest 2002; 122: 289-293.
Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005; 166: 399- 407.
Yasuoka H, Zhou Z, Pilewski JM, Oury TD, Choi AM, FeghaliBostwick CA. Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol 2006; 169: 1633-1642.
Lebtahi R, Moreau S, Marchand-Adam S, Debray MP, Brauner M, Soler P, Marchal J, Raguin O, Gruaz-Guyon A, Reubi JC et al. Increased uptake of 111In- octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006; 47: 1281-1287.
Borie R, Fabre A, Prost F, Marchal-Somme J, Lebtahi R, Marchand-Adam S, Aubier M, Soler P, Crestani B. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax 2008; 63: 251-258.
Tug T, Kara H, Karaoglu A, Karatas F, Turgut NH, Ayan E, Boran C, Tug E. The effect of octreotide, an analog of somatostatin, on bleomycin-induced interstitial pulmonary fibrosis in rats. Drug Chem Toxicol 2013; 36: 181-186.
Crestani B, Chapron J, Wallaert B, Bergot E, Delaval P, IsraelBiet D, Lacronique J, Monnet I, Reynaud-Gaubert M, Tazi A et al. Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study. Eur Respir J 2012; 39: 772-775.
Yamamoto T. Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma. Clin Immunol 2002; 102: 209-216.
Jia WD, Xu GL, Wang W, Wang ZH, Li JS, Ma JL, Ren WH, Ge YS, Yu JH, Liu WB. A somatostatin analogue, octreotide, inhibits the occurrence of second primary tumors and lung metastasis after resection of hepatocellular carcinoma in mice. Tohoku J Exp Med 2009; 218: 155-160.
Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 2009; 30: 417-437.
Aston C, Jagirdar J, Lee TC. Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151: 1597-1603.
Yasuoka H, Larregina AT, Yamaguchi Y, Feghali-Bostwick CA. Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins. Open Rheumatol J 2008; 2: 17-22.
Thiebaud D, Ng KW, Findlay DM, Harker M, Martin TJ. Insulinlike growth factor I regulates mRNA levels of osteonectin and pro-alpha-I (i)-collagen in clonal proosteoblastic calvarial cells. J Bone Miner Res 1990; 5: 761-767.
Barreca A, De Luca M, Del Monte P, Bondanza S, Damonte G, Cariola G, Di Marco E, Giordano G, Cancedda R, Minuto F. In vitro paracrine regulation of human keratinocyte growth by fibroblast-derived insulin like growth factors. J Cell Physiol 1992; 151: 262-268.
Shinohara M, Hamasaki Y, Katayama I. Refractory pretibial myxoedema with response to intralesional insulin-like growth factor I antagonist (octreotide): down regulation of hyaluronic acid production by the lesional fibroblasts. Br J Dermatol 2000; 143: 1083-1086.
Pavlovic M, Saiag P, Lotz JP, Marinho E, Clerici T, Izrael V. Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide. Arch Dermatol 1995; 131: 1207-1208.